122 related articles for article (PubMed ID: 33675910)
21. PI3K/PTEN/AKT/mTOR polymorphisms: association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab-docetaxel.
Pfisterer K; Fusi A; Klinghammer K; Knödler M; Nonnenmacher A; Keilholz U
Head Neck; 2015 Apr; 37(4):471-8. PubMed ID: 24421178
[TBL] [Abstract][Full Text] [Related]
22. The PI3K/Akt Pathway Regulates Oxygen Metabolism via Pyruvate Dehydrogenase (PDH)-E1α Phosphorylation.
Cerniglia GJ; Dey S; Gallagher-Colombo SM; Daurio NA; Tuttle S; Busch TM; Lin A; Sun R; Esipova TV; Vinogradov SA; Denko N; Koumenis C; Maity A
Mol Cancer Ther; 2015 Aug; 14(8):1928-38. PubMed ID: 25995437
[TBL] [Abstract][Full Text] [Related]
23. Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival.
Pande M; Bondy ML; Do KA; Sahin AA; Ying J; Mills GB; Thompson PA; Brewster AM
Breast Cancer Res Treat; 2014 Sep; 147(2):381-7. PubMed ID: 25108739
[TBL] [Abstract][Full Text] [Related]
24. Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers.
Houédé N; Pourquier P
Pharmacol Ther; 2015 Jan; 145():1-18. PubMed ID: 24929024
[TBL] [Abstract][Full Text] [Related]
25. Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
Wirtz ED; Hoshino D; Maldonado AT; Tyson DR; Weaver AM
JAMA Otolaryngol Head Neck Surg; 2015 Jun; 141(6):543-9. PubMed ID: 25855885
[TBL] [Abstract][Full Text] [Related]
26. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.
Lui VW; Hedberg ML; Li H; Vangara BS; Pendleton K; Zeng Y; Lu Y; Zhang Q; Du Y; Gilbert BR; Freilino M; Sauerwein S; Peyser ND; Xiao D; Diergaarde B; Wang L; Chiosea S; Seethala R; Johnson JT; Kim S; Duvvuri U; Ferris RL; Romkes M; Nukui T; Kwok-Shing Ng P; Garraway LA; Hammerman PS; Mills GB; Grandis JR
Cancer Discov; 2013 Jul; 3(7):761-9. PubMed ID: 23619167
[TBL] [Abstract][Full Text] [Related]
27. Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies.
Keppler-Noreuil KM; Parker VE; Darling TN; Martinez-Agosto JA
Am J Med Genet C Semin Med Genet; 2016 Dec; 172(4):402-421. PubMed ID: 27860216
[TBL] [Abstract][Full Text] [Related]
28. The effect of LKB1 on the PI3K/Akt pathway activation in association with PTEN and PIK3CA in HNC.
Ekizoglu S; Dogan S; Ulker D; Seven D; Gozen ED; Karaman E; Buyru N
Clin Otolaryngol; 2015 Dec; 40(6):622-8. PubMed ID: 25850957
[TBL] [Abstract][Full Text] [Related]
29. The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies.
Vander Broek R; Mohan S; Eytan DF; Chen Z; Van Waes C
Oral Dis; 2015 Oct; 21(7):815-25. PubMed ID: 24219320
[TBL] [Abstract][Full Text] [Related]
30. Curcumin downregulates the PI3K-AKT-mTOR pathway and inhibits growth and progression in head and neck cancer cells.
Borges GA; Elias ST; Amorim B; de Lima CL; Coletta RD; Castilho RM; Squarize CH; Guerra ENS
Phytother Res; 2020 Dec; 34(12):3311-3324. PubMed ID: 32628350
[TBL] [Abstract][Full Text] [Related]
31. Activation of PI3K/Akt/mTOR signaling pathway triggered by PTEN downregulation in the pathogenesis of Crohn's disease.
Long SH; He Y; Chen MH; Cao K; Chen YJ; Chen BL; Mao R; Zhang SH; Zhu ZH; Zeng ZR; Hu PJ
J Dig Dis; 2013 Dec; 14(12):662-9. PubMed ID: 23962154
[TBL] [Abstract][Full Text] [Related]
32. Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer.
Chen J; Zhao KN; Li R; Shao R; Chen C
Curr Med Chem; 2014; 21(26):3070-80. PubMed ID: 24735369
[TBL] [Abstract][Full Text] [Related]
33. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
Mabuchi S; Kuroda H; Takahashi R; Sasano T
Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
[TBL] [Abstract][Full Text] [Related]
34. PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas.
Nozhat Z; Hedayati M
Mol Diagn Ther; 2016 Feb; 20(1):13-26. PubMed ID: 26597586
[TBL] [Abstract][Full Text] [Related]
35. PIK3CA copy number aberration and activation of the PI3K-AKT-mTOR pathway in varied disease states of penile cancer.
Adimonye A; Stankiewicz E; La-Touche S; Kudahetti S; Trevisan G; Tinwell B; Corbishley C; Lu YJ; Watkin N; Berney D
PLoS One; 2018; 13(6):e0198905. PubMed ID: 29902261
[TBL] [Abstract][Full Text] [Related]
36. Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics.
Costa C; Pereira S; Lima L; Peixoto A; Fernandes E; Neves D; Neves M; Gaiteiro C; Tavares A; Gil da Costa RM; Cruz R; Amaro T; Oliveira PA; Ferreira JA; Santos LL
PLoS One; 2015; 10(11):e0141253. PubMed ID: 26569621
[TBL] [Abstract][Full Text] [Related]
37. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.
Hou MM; Liu X; Wheler J; Naing A; Hong D; Coleman RL; Tsimberidou A; Janku F; Zinner R; Lu K; Kurzrock R; Fu S
Oncotarget; 2014 Nov; 5(22):11168-79. PubMed ID: 25426553
[TBL] [Abstract][Full Text] [Related]
38. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
Kim A; Lee JE; Lee SS; Kim C; Lee SJ; Jang WS; Park S
Int J Cancer; 2013 Aug; 133(4):984-96. PubMed ID: 23475782
[TBL] [Abstract][Full Text] [Related]
39. Mutation Profiling of Usual Ductal Hyperplasia of the Breast Reveals Activating Mutations Predominantly at Different Levels of the PI3K/AKT/mTOR Pathway.
Jahn SW; Kashofer K; Thüringer A; Abete L; Winter E; Eidenhammer S; Viertler C; Tavassoli F; Moinfar F
Am J Pathol; 2016 Jan; 186(1):15-23. PubMed ID: 26718977
[TBL] [Abstract][Full Text] [Related]
40. PI3K/Akt/mTOR signaling & its regulator tumour suppressor genes
Makker A; Goel MM; Mahdi AA; Bhatia V; Das V; Agarwal A; Pandey A
Indian J Med Res; 2016 May; 143(Supplement):S112-S119. PubMed ID: 27748285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]